SBIR/STTR Research Award
IMMUNOTOXIN THERAPY OF ALLERGY
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1989Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- IMMUNETICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
FOLLOWING ON SUCCESS IN A MURINE MODEL SYSTEM, A HUMAN IGE-SPECIFIC IMMUNOTOXIN WILL BE SYNTHESIZED AND EVALUATED FOR EFFICACY AGAINST AN IGE-SECRETING HUMAN MYELOMA CELL LINE. MONOCLONAL ANTIHUMAN IGE ANTIBODY WILL BE COVALENTLY ATTACHED TO A VARIETY OF CYTOTOXINS TO PRODUCE A HUMAN IGE-SPECIFIC IMMUNOTOXIN. THIS REAGENT WILL BE TESTED FOR SPECIFIC CYTOTOXICITY AGAINST THE HUMAN IGE MYELOMA LINE IN VITRO. THE IN VITRO-SELECTED IMMUNOTOXIN FORMULATION WILL BE EVALUATED IN VIVO BY ESTABLISHING THE MYELOMA LINE IN NU/NU MICE AND ATTEMPTING TO MODULATE HUMAN SERUM IGE LEVELS BY PARENTERAL ADMINISTRATION OF IMMUNOTOXIN. THE ULTIMATE GOAL OF THIS RESEARCH IS TO PROVIDE IMPROVED ALLERGY THERAPY VIA IGE-SPECIFIC IMMUNOTOXINS.
Technology keywords
Not reported